RARE vs. RCL
Compare and contrast key facts about Ultragenyx Pharmaceutical Inc. (RARE) and Royal Caribbean Cruises Ltd. (RCL).
Performance
RARE vs. RCL - Performance Comparison
Loading graphics...
RARE vs. RCL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RARE Ultragenyx Pharmaceutical Inc. | -8.91% | -45.33% | -12.02% | 3.22% | -44.90% | -39.25% | 224.12% | -1.77% | -6.25% | -34.03% |
RCL Royal Caribbean Cruises Ltd. | -0.82% | 22.46% | 78.98% | 161.97% | -35.72% | 2.96% | -43.50% | 39.94% | -16.13% | 48.22% |
Fundamentals
RARE:
$2.09B
RCL:
$75.12B
RARE:
-$5.79
RCL:
$15.59
RARE:
3.09
RCL:
4.20
RARE:
129.52
RCL:
7.48
RARE:
$672.72M
RCL:
$17.94B
RARE:
$564.07M
RCL:
$8.40B
RARE:
-$488.57M
RCL:
$6.90B
Returns By Period
In the year-to-date period, RARE achieves a -8.91% return, which is significantly lower than RCL's -0.82% return. Over the past 10 years, RARE has underperformed RCL with an annualized return of -10.90%, while RCL has yielded a comparatively higher 14.21% annualized return.
RARE
- 1D
- 8.55%
- 1M
- -10.43%
- YTD
- -8.91%
- 6M
- -30.35%
- 1Y
- -42.14%
- 3Y*
- -19.46%
- 5Y*
- -28.64%
- 10Y*
- -10.90%
RCL
- 1D
- 5.28%
- 1M
- -11.03%
- YTD
- -0.82%
- 6M
- -14.21%
- 1Y
- 35.92%
- 3Y*
- 62.75%
- 5Y*
- 26.57%
- 10Y*
- 14.21%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RARE vs. RCL — Risk / Return Rank
RARE
RCL
RARE vs. RCL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and Royal Caribbean Cruises Ltd. (RCL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RARE | RCL | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.59 | 0.74 | -1.33 |
Sortino ratioReturn per unit of downside risk | -0.42 | 1.40 | -1.81 |
Omega ratioGain probability vs. loss probability | 0.93 | 1.18 | -0.25 |
Calmar ratioReturn relative to maximum drawdown | -0.81 | 1.07 | -1.87 |
Martin ratioReturn relative to average drawdown | -1.53 | 2.19 | -3.72 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| RARE | RCL | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.59 | 0.74 | -1.33 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.53 | 0.56 | -1.09 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.20 | 0.27 | -0.47 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.10 | 0.26 | -0.36 |
Correlation
The correlation between RARE and RCL is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
RARE vs. RCL - Dividend Comparison
RARE has not paid dividends to shareholders, while RCL's dividend yield for the trailing twelve months is around 1.54%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RARE Ultragenyx Pharmaceutical Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
RCL Royal Caribbean Cruises Ltd. | 1.54% | 1.25% | 0.41% | 0.00% | 0.00% | 0.00% | 1.04% | 2.22% | 2.66% | 1.81% | 2.08% | 1.33% |
Drawdowns
RARE vs. RCL - Drawdown Comparison
The maximum RARE drawdown since its inception was -89.57%, roughly equal to the maximum RCL drawdown of -89.49%. Use the drawdown chart below to compare losses from any high point for RARE and RCL.
Loading graphics...
Drawdown Indicators
| RARE | RCL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.57% | -89.49% | -0.08% |
Max Drawdown (1Y)Largest decline over 1 year | -55.36% | -32.36% | -23.00% |
Max Drawdown (5Y)Largest decline over 5 years | -84.01% | -67.75% | -16.26% |
Max Drawdown (10Y)Largest decline over 10 years | -89.57% | -83.30% | -6.27% |
Current DrawdownCurrent decline from peak | -88.19% | -23.89% | -64.30% |
Average DrawdownAverage peak-to-trough decline | -54.28% | -27.79% | -26.49% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.21% | 15.76% | +13.45% |
Volatility
RARE vs. RCL - Volatility Comparison
Ultragenyx Pharmaceutical Inc. (RARE) has a higher volatility of 18.67% compared to Royal Caribbean Cruises Ltd. (RCL) at 15.36%. This indicates that RARE's price experiences larger fluctuations and is considered to be riskier than RCL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| RARE | RCL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.67% | 15.36% | +3.31% |
Volatility (6M)Calculated over the trailing 6-month period | 67.87% | 36.10% | +31.77% |
Volatility (1Y)Calculated over the trailing 1-year period | 71.96% | 48.47% | +23.49% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.11% | 48.11% | +6.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 55.61% | 53.05% | +2.56% |
Financials
RARE vs. RCL - Financials Comparison
This section allows you to compare key financial metrics between Ultragenyx Pharmaceutical Inc. and Royal Caribbean Cruises Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RARE vs. RCL - Profitability Comparison
RARE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Ultragenyx Pharmaceutical Inc. reported a gross profit of 178.00M and revenue of 207.00M. Therefore, the gross margin over that period was 86.0%.
RCL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Royal Caribbean Cruises Ltd. reported a gross profit of 1.56B and revenue of 4.26B. Therefore, the gross margin over that period was 36.7%.
RARE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Ultragenyx Pharmaceutical Inc. reported an operating income of -114.00M and revenue of 207.00M, resulting in an operating margin of -55.1%.
RCL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Royal Caribbean Cruises Ltd. reported an operating income of 933.00M and revenue of 4.26B, resulting in an operating margin of 21.9%.
RARE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Ultragenyx Pharmaceutical Inc. reported a net income of -129.00M and revenue of 207.00M, resulting in a net margin of -62.3%.
RCL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Royal Caribbean Cruises Ltd. reported a net income of 754.00M and revenue of 4.26B, resulting in a net margin of 17.7%.